The University of Chicago Header Logo

Connection

Koen Van Besien to Hematopoietic Stem Cell Transplantation

Back to Details
This is a "connection" page, showing publications Koen Van Besien has written about Hematopoietic Stem Cell Transplantation.
Koen Van Besien
Connection Strength
21.690
Hematopoietic Stem Cell Transplantation
  1. Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2023 12; 64(13):2214-2216.
    View in: PubMed
    Score: 0.540
  2. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023 07; 58(7):835-838.
    View in: PubMed
    Score: 0.525
  3. Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 05; 29(5):326.e1-326.e10.
    View in: PubMed
    Score: 0.518
  4. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation. Transplant Cell Ther. 2022 09; 28(9):618.e1-618.e10.
    View in: PubMed
    Score: 0.496
  5. Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leuk Lymphoma. 2022 02; 63(2):435-442.
    View in: PubMed
    Score: 0.473
  6. Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. Leuk Lymphoma. 2021 10; 62(10):2306-2309.
    View in: PubMed
    Score: 0.472
  7. Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. Leuk Lymphoma. 2021 02; 62(2):255-256.
    View in: PubMed
    Score: 0.448
  8. Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected? Leuk Lymphoma. 2020 12; 61(12):2783-2784.
    View in: PubMed
    Score: 0.439
  9. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020 12; 61(12):3024-3026.
    View in: PubMed
    Score: 0.434
  10. Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts? Leuk Lymphoma. 2020 04; 61(4):753-756.
    View in: PubMed
    Score: 0.421
  11. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 04; 26(4):789-797.
    View in: PubMed
    Score: 0.418
  12. Donor graft genotypes versus leukemia. Leuk Lymphoma. 2019 07; 60(7):1606-1607.
    View in: PubMed
    Score: 0.404
  13. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103.
    View in: PubMed
    Score: 0.403
  14. A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5.
    View in: PubMed
    Score: 0.377
  15. Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience. Transfusion. 2018 02; 58(2):339-344.
    View in: PubMed
    Score: 0.362
  16. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017 01; 58(1):230-232.
    View in: PubMed
    Score: 0.326
  17. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
    View in: PubMed
    Score: 0.320
  18. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.319
  19. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.
    View in: PubMed
    Score: 0.313
  20. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036.
    View in: PubMed
    Score: 0.312
  21. A new "age" for high dose therapy and autologous stem cell transplant. Leuk Lymphoma. 2015; 56(8):2233-4.
    View in: PubMed
    Score: 0.299
  22. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2.
    View in: PubMed
    Score: 0.298
  23. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014 Jun; 55(6):1221-2.
    View in: PubMed
    Score: 0.284
  24. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
    View in: PubMed
    Score: 0.284
  25. Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7.
    View in: PubMed
    Score: 0.279
  26. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 May; 49(5):722-4.
    View in: PubMed
    Score: 0.278
  27. Therapeutic drug monitoring: a way to improve long-term immunological balance? Leuk Lymphoma. 2013 Jan; 54(1):5-6.
    View in: PubMed
    Score: 0.251
  28. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9.
    View in: PubMed
    Score: 0.235
  29. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leuk Lymphoma. 2011 Aug; 52(8):1415-7.
    View in: PubMed
    Score: 0.233
  30. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111.
    View in: PubMed
    Score: 0.232
  31. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Feb; 47(2):217-26.
    View in: PubMed
    Score: 0.228
  32. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
    View in: PubMed
    Score: 0.223
  33. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.220
  34. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
    View in: PubMed
    Score: 0.218
  35. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956.
    View in: PubMed
    Score: 0.212
  36. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.207
  37. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.
    View in: PubMed
    Score: 0.202
  38. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63.
    View in: PubMed
    Score: 0.198
  39. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res. 2009; 144:209-32.
    View in: PubMed
    Score: 0.195
  40. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8.
    View in: PubMed
    Score: 0.195
  41. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.193
  42. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2.
    View in: PubMed
    Score: 0.191
  43. Superiority of reduced-intensity conditioning for Hodgkin's lymphoma. J Clin Oncol. 2008 Aug 20; 26(24):4045-6; author reply 4046-7.
    View in: PubMed
    Score: 0.190
  44. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13.
    View in: PubMed
    Score: 0.181
  45. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.178
  46. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.178
  47. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.166
  48. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006 Sep; 20(5):235-44.
    View in: PubMed
    Score: 0.160
  49. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol. 2005 Aug; 32(4):414-21.
    View in: PubMed
    Score: 0.154
  50. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70.
    View in: PubMed
    Score: 0.151
  51. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004 Dec; 34(11):929-38.
    View in: PubMed
    Score: 0.147
  52. High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role? Cells. 2024 10 27; 13(21).
    View in: PubMed
    Score: 0.146
  53. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10; 43(2):201-213.
    View in: PubMed
    Score: 0.145
  54. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024 06 25; 8(12):3001-3012.
    View in: PubMed
    Score: 0.143
  55. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9.
    View in: PubMed
    Score: 0.134
  56. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023 03 16; 186(6):1115-1126.e8.
    View in: PubMed
    Score: 0.131
  57. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2022 09; 57(9):1445-1447.
    View in: PubMed
    Score: 0.124
  58. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood. 2002 Jun 01; 99(11):4251-2; author reply 4252.
    View in: PubMed
    Score: 0.124
  59. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8.
    View in: PubMed
    Score: 0.122
  60. Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
    View in: PubMed
    Score: 0.120
  61. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022 02; 63(2):473-477.
    View in: PubMed
    Score: 0.118
  62. Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2021 10 05; 73(7):1257-1265.
    View in: PubMed
    Score: 0.118
  63. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplant Cell Ther. 2021 12; 27(12):993.e1-993.e8.
    View in: PubMed
    Score: 0.118
  64. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001 Sep; 28(6):545-9.
    View in: PubMed
    Score: 0.117
  65. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62.
    View in: PubMed
    Score: 0.117
  66. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020 10 23; 71(7):1693-1700.
    View in: PubMed
    Score: 0.111
  67. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021 01; 203(1):96-104.
    View in: PubMed
    Score: 0.109
  68. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9.
    View in: PubMed
    Score: 0.109
  69. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.
    View in: PubMed
    Score: 0.108
  70. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020 02 25; 4(4):740-754.
    View in: PubMed
    Score: 0.106
  71. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.101
  72. Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018 11 13; 67(11):1720-1728.
    View in: PubMed
    Score: 0.097
  73. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 07; 54(7):1058-1066.
    View in: PubMed
    Score: 0.096
  74. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.
    View in: PubMed
    Score: 0.092
  75. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.091
  76. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S54-8.
    View in: PubMed
    Score: 0.090
  77. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9.
    View in: PubMed
    Score: 0.087
  78. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.
    View in: PubMed
    Score: 0.086
  79. Second allogeneic transplantation: ever? never? or sometimes. Leuk Lymphoma. 2017 06; 58(6):1279-1280.
    View in: PubMed
    Score: 0.084
  80. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266.
    View in: PubMed
    Score: 0.082
  81. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349.
    View in: PubMed
    Score: 0.081
  82. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356.
    View in: PubMed
    Score: 0.081
  83. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
    View in: PubMed
    Score: 0.076
  84. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73.
    View in: PubMed
    Score: 0.072
  85. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.071
  86. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014 Dec; 55(12):2858-65.
    View in: PubMed
    Score: 0.070
  87. Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8.
    View in: PubMed
    Score: 0.070
  88. Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism. 2014; 5(2):24-39.
    View in: PubMed
    Score: 0.069
  89. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.068
  90. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.068
  91. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3100-9.
    View in: PubMed
    Score: 0.067
  92. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.066
  93. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5.
    View in: PubMed
    Score: 0.066
  94. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7.
    View in: PubMed
    Score: 0.065
  95. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
    View in: PubMed
    Score: 0.064
  96. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013 Mar; 19(3):429-34.
    View in: PubMed
    Score: 0.064
  97. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013 Apr; 54(4):885-8.
    View in: PubMed
    Score: 0.063
  98. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8.
    View in: PubMed
    Score: 0.061
  99. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7.
    View in: PubMed
    Score: 0.061
  100. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1255-64.
    View in: PubMed
    Score: 0.060
  101. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.059
  102. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54.
    View in: PubMed
    Score: 0.056
  103. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.054
  104. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.054
  105. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8.
    View in: PubMed
    Score: 0.053
  106. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4.
    View in: PubMed
    Score: 0.053
  107. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68.
    View in: PubMed
    Score: 0.053
  108. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun; 45(6):1068-76.
    View in: PubMed
    Score: 0.052
  109. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45.
    View in: PubMed
    Score: 0.051
  110. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9.
    View in: PubMed
    Score: 0.051
  111. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7.
    View in: PubMed
    Score: 0.050
  112. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17.
    View in: PubMed
    Score: 0.049
  113. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec; 14(12):1323-33.
    View in: PubMed
    Score: 0.048
  114. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15; 112(6):2585-6; author reply 2586-7.
    View in: PubMed
    Score: 0.048
  115. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12.
    View in: PubMed
    Score: 0.047
  116. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41.
    View in: PubMed
    Score: 0.047
  117. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008 Jun; 14(6):719-23.
    View in: PubMed
    Score: 0.047
  118. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb; 14(2):236-45.
    View in: PubMed
    Score: 0.046
  119. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma. 2006 Aug; 47(8):1447-8.
    View in: PubMed
    Score: 0.041
  120. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24.
    View in: PubMed
    Score: 0.041
  121. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541-51.
    View in: PubMed
    Score: 0.041
  122. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006 May; 7(5):436-8.
    View in: PubMed
    Score: 0.041
  123. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant. 2005 Dec; 11(12):988-98.
    View in: PubMed
    Score: 0.039
  124. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
    View in: PubMed
    Score: 0.037
  125. Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplant Cell Ther. 2024 Nov; 30(11):1100.e1-1100.e11.
    View in: PubMed
    Score: 0.036
  126. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01; 104(12):3797-803.
    View in: PubMed
    Score: 0.036
  127. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.035
  128. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15; 21(20):3744-53.
    View in: PubMed
    Score: 0.034
  129. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.
    View in: PubMed
    Score: 0.034
  130. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
    View in: PubMed
    Score: 0.033
  131. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700.
    View in: PubMed
    Score: 0.029
  132. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25.
    View in: PubMed
    Score: 0.029
  133. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001 Mar 15; 19(6):1855-64.
    View in: PubMed
    Score: 0.028
  134. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44.
    View in: PubMed
    Score: 0.028
  135. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96.
    View in: PubMed
    Score: 0.028
  136. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15; 19(2):406-13.
    View in: PubMed
    Score: 0.028
  137. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.
    View in: PubMed
    Score: 0.027
  138. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.026
  139. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.026
  140. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.025
  141. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul; 24(1):57-61.
    View in: PubMed
    Score: 0.025
  142. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.025
  143. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb; 17(2):534-45.
    View in: PubMed
    Score: 0.025
  144. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 1999; 5(1):36-45.
    View in: PubMed
    Score: 0.024
  145. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.023
  146. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplant. 2017 Dec; 52(12):1643-1650.
    View in: PubMed
    Score: 0.022
  147. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
    View in: PubMed
    Score: 0.022
  148. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
    View in: PubMed
    Score: 0.022
  149. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.021
  150. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4.
    View in: PubMed
    Score: 0.021
  151. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73.
    View in: PubMed
    Score: 0.021
  152. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42.
    View in: PubMed
    Score: 0.021
  153. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90.
    View in: PubMed
    Score: 0.021
  154. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.021
  155. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May; 22(5):965-70.
    View in: PubMed
    Score: 0.020
  156. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.019
  157. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
    View in: PubMed
    Score: 0.019
  158. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
    View in: PubMed
    Score: 0.019
  159. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8.
    View in: PubMed
    Score: 0.017
  160. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32.
    View in: PubMed
    Score: 0.014
  161. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82.
    View in: PubMed
    Score: 0.012
  162. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.012
  163. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74.
    View in: PubMed
    Score: 0.012
  164. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82.
    View in: PubMed
    Score: 0.008
  165. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
    View in: PubMed
    Score: 0.007
  166. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.
    View in: PubMed
    Score: 0.006
  167. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.